Pursuant to the Securities Purchase Agreement, Compass Therapeutics, Inc. has agreed to appoint James P. Boylan, the Chief Executive Officer of Enavate Sciences, as a Class II director to join the Board of Directors of the company, with a term expiring at the Company's annual meeting of stockholders in 2025. On November 1, 2022, the Board appointed Mr. Boylan to join as a director of the Board, effective upon the closing of the Private Placement. The Board determined that Mr. Boylan is independent within the meaning of Nasdaq's listing rules.

Mr. Boylan, aged 55, is the Chief Executive Officer of Enavate Sciences, a portfolio company of Patient Square Capital. Mr. Boylan is an experienced executive, entrepreneur and innovator with nearly three decades of health care experience. Prior to joining Enavate Sciences in May 2022, Mr. Boylan was the President and Head of Investment Banking of SVB Leerink, which he joined in May 2009 and where he architected and led the transformation of Leerink Swann into an industry-leading health care investment bank that was acquired by SVB Financial in 2019.

Across his 12 years at SVB Leerink and prior 12 years as a Managing Director at Merrill Lynch, Mr. Boylan has worked with numerous healthcare and biotechnology companies to develop strategy and complete transactions in capital markets and mergers & acquisitions. Mr. Boylan has a broad network of CEO, CFO, board member, venture capital and investor relationships in the health care field. Mr. Boylan earned an MBA in finance from the Columbia Business School and a BS in finance from Lehigh University.